ATYR (aTyr Pharma) Future Policy Benefits

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATYR aTyr Pharma Inc ATYR
20 GF Score
Price $0.38
GF Value $0.52
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is aTyr Pharma Future Policy Benefits?

Future Policy Benefits only applies to insurance companies.

ATYR
20GF Score
aTyr Pharma Inc ATYR
Future Policy Benefits is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is aTyr Pharma (ATYR) Overvalued in 2026?

Based on GuruFocus' analysis, aTyr Pharma stock appears to be undervalued. The current stock price of $0.38 is trading 26.5% below its estimated GF Value™ of $0.52. GuruFocus considers aTyr Pharma to be Modestly Undervalued.

Key valuation signals for ATYR:

  • Future Policy Benefits:
  • GF Value™: $0.52 vs. price of $0.38 (26.5% below fair value)
  • GF Score™: 20/100 with 3 warning signs

No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

aTyr Pharma Business Description

Other Exchanges 471A:Germany
Address 10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
20GF Score

Get the complete analysis for ATYR

Future Policy Benefits is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.38
Price
$0.52
GF Value